Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

Part of paid clinical trials in Pheonix, Arizona.

Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Study ID
NCT06963281
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • IBI3020 — DRUG
    Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection

Study Details

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

Key Dates

Start date
Apr 29, 2025
Status verified
Jun 2025
Primary completion
Dec 31, 2027
Completion
Mar 31, 2028

Study Design

Enrollment
285 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: IBI3020

Primary Outcome Measure

Numbers of subjects with adverse events [ Time Frame: Up to 3 years ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Mayo Clinic - ArizonaPheonixArizona85054
Mitesh Borad, Dr
[email protected]
480-301-8000
Mayo Clinic - FloridaJacksonvilleFlorida32224
Yanyan Lou, Dr.
[email protected]
(480) 342-2000
Mayo Clinic - RochesterRochesterMinnesota55905
Hao Xie, Dr
[email protected]
(507) 512-1667
Montefiore Cancer CenterNew YorkNew York10461
Fernand Bteich, Dr.
[email protected]
(718) 405-8124
NEXT HoustonHoustonTexas77054
Jennifer Segar
[email protected]
832-384-7900
NEXT DallasIrvingTexas75039
Shiraj Sen
[email protected]
972-893-8800

Find similar trials in Pheonix, AZ

By research site
Mayo Clinic - Arizona· Pheonix, AZMayo Clinic - Florida· Jacksonville, FLMayo Clinic - Rochester· Rochester, MNMontefiore Cancer Center· New York, NYNEXT Houston· Houston, TXNEXT Dallas· Irving, TX

Related Studies